Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failure
Introduction: We investigated the factors associated with readmission in patients with congestive heart failure (HF) receiving long-term administration of tolvaptan (TLV) to support treatment decisions for HF. Methods: This retrospective cohort study included 181 patients with congestive HF who rece...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer – Medknow Publications
2024-11-01
|
| Series: | Singapore Medical Journal |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/singaporemedj.SMJ-2021-348 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863761361960960 |
|---|---|
| author | Shoko Yamashita Miki Takenaka Masayuki Ohbayashi Noriko Kohyama Tatsuya Kurihara Tomiko Sunaga Hisaaki Ishiguro Mari Kogo |
| author_facet | Shoko Yamashita Miki Takenaka Masayuki Ohbayashi Noriko Kohyama Tatsuya Kurihara Tomiko Sunaga Hisaaki Ishiguro Mari Kogo |
| author_sort | Shoko Yamashita |
| collection | DOAJ |
| description | Introduction:
We investigated the factors associated with readmission in patients with congestive heart failure (HF) receiving long-term administration of tolvaptan (TLV) to support treatment decisions for HF.
Methods:
This retrospective cohort study included 181 patients with congestive HF who received long-term administration of TLV. Long-term administration of TLV was defined as the administration of TLV for 60 days or longer. The outcome was a readmission event for worsening HF within 1 year after discharge. Significant factors associated with readmission were selected using multivariate analysis. To compare the time to readmission using significant factors extracted in a multivariate analysis, readmission curves were constructed using the Kaplan–Meier method and analysed using the log-rank test.
Results:
The median age was 78 years (range, 38–96 years), 117 patients (64.6%) were males, and 77 patients (42.5%) had a hospitalisation history of HF. Readmission for worsening HF within 1 year after long-term TLV treatment occurred in 62 patients (34.3%). In the multivariate analysis, estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (odds ratio, 3.22; 95% confidence interval, 1.661–6.249; P = 0.001) was an independent significant factor. When eGFR at discharge was divided into two groups (eGFR < 30 vs. eGFR ≥ 30), readmission rates within 1 year were 53.3% vs. 25.4%, respectively (P = 0.001).
Conclusion:
We revealed that eGFR was strongly associated with readmission in patients with HF who received long-term administration of TLV. Furthermore, we showed that eGFR is an important indicator in guiding treatment of HF in patients receiving TLV. |
| format | Article |
| id | doaj-art-55835939b30c45208edccdb79f7ef5a0 |
| institution | Kabale University |
| issn | 0037-5675 2737-5935 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wolters Kluwer – Medknow Publications |
| record_format | Article |
| series | Singapore Medical Journal |
| spelling | doaj-art-55835939b30c45208edccdb79f7ef5a02025-02-09T10:27:44ZengWolters Kluwer – Medknow PublicationsSingapore Medical Journal0037-56752737-59352024-11-01651161462310.4103/singaporemedj.SMJ-2021-348Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failureShoko YamashitaMiki TakenakaMasayuki OhbayashiNoriko KohyamaTatsuya KuriharaTomiko SunagaHisaaki IshiguroMari KogoIntroduction: We investigated the factors associated with readmission in patients with congestive heart failure (HF) receiving long-term administration of tolvaptan (TLV) to support treatment decisions for HF. Methods: This retrospective cohort study included 181 patients with congestive HF who received long-term administration of TLV. Long-term administration of TLV was defined as the administration of TLV for 60 days or longer. The outcome was a readmission event for worsening HF within 1 year after discharge. Significant factors associated with readmission were selected using multivariate analysis. To compare the time to readmission using significant factors extracted in a multivariate analysis, readmission curves were constructed using the Kaplan–Meier method and analysed using the log-rank test. Results: The median age was 78 years (range, 38–96 years), 117 patients (64.6%) were males, and 77 patients (42.5%) had a hospitalisation history of HF. Readmission for worsening HF within 1 year after long-term TLV treatment occurred in 62 patients (34.3%). In the multivariate analysis, estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (odds ratio, 3.22; 95% confidence interval, 1.661–6.249; P = 0.001) was an independent significant factor. When eGFR at discharge was divided into two groups (eGFR < 30 vs. eGFR ≥ 30), readmission rates within 1 year were 53.3% vs. 25.4%, respectively (P = 0.001). Conclusion: We revealed that eGFR was strongly associated with readmission in patients with HF who received long-term administration of TLV. Furthermore, we showed that eGFR is an important indicator in guiding treatment of HF in patients receiving TLV.https://journals.lww.com/10.4103/singaporemedj.SMJ-2021-348heart failurelong-term administrationreadmissiontolvaptan |
| spellingShingle | Shoko Yamashita Miki Takenaka Masayuki Ohbayashi Noriko Kohyama Tatsuya Kurihara Tomiko Sunaga Hisaaki Ishiguro Mari Kogo Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failure Singapore Medical Journal heart failure long-term administration readmission tolvaptan |
| title | Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failure |
| title_full | Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failure |
| title_fullStr | Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failure |
| title_full_unstemmed | Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failure |
| title_short | Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failure |
| title_sort | factors associated with readmission after long term administration of tolvaptan in patients with congestive heart failure |
| topic | heart failure long-term administration readmission tolvaptan |
| url | https://journals.lww.com/10.4103/singaporemedj.SMJ-2021-348 |
| work_keys_str_mv | AT shokoyamashita factorsassociatedwithreadmissionafterlongtermadministrationoftolvaptaninpatientswithcongestiveheartfailure AT mikitakenaka factorsassociatedwithreadmissionafterlongtermadministrationoftolvaptaninpatientswithcongestiveheartfailure AT masayukiohbayashi factorsassociatedwithreadmissionafterlongtermadministrationoftolvaptaninpatientswithcongestiveheartfailure AT norikokohyama factorsassociatedwithreadmissionafterlongtermadministrationoftolvaptaninpatientswithcongestiveheartfailure AT tatsuyakurihara factorsassociatedwithreadmissionafterlongtermadministrationoftolvaptaninpatientswithcongestiveheartfailure AT tomikosunaga factorsassociatedwithreadmissionafterlongtermadministrationoftolvaptaninpatientswithcongestiveheartfailure AT hisaakiishiguro factorsassociatedwithreadmissionafterlongtermadministrationoftolvaptaninpatientswithcongestiveheartfailure AT marikogo factorsassociatedwithreadmissionafterlongtermadministrationoftolvaptaninpatientswithcongestiveheartfailure |